Recombinant Botulinum Neurotoxin Hc Subunit (BoNT Hc) and Catalytically Inactive Clostridium botulinum Holoproteins (ciBoNT HPs) as Vaccine Candidates for the Prevention of Botulism

• Published in: Toxins 2017-09, Vol.9 (9), p.269
• Main Authors: Webb, Robert P, Smith, Theresa J, Smith, Leonard A, Wright, Patrick M, Guernieri, Rebecca L, Brown, Jennifer L, Skerry, Janet C
• Format: Article
• Language: English
• Subjects: Amino Acid Sequence; Amino acids; Animals; Antigens; Bacterial Proteins - immunology; Bacterial Vaccines - chemistry; Bacterial Vaccines - pharmacology; BoNT mosaic toxin; BoNT subtype toxin; botulinum neurotoxin (BoNT); Botulinum toxin; Botulinum Toxins - immunology; Botulism; Botulism - prevention & control; catalytically inactive BoNT holoprotein (ciBoNT HP); Clostridium botulinum; Disease control; Food contamination; Genetic engineering; Heterogeneity; Homology; Immunity; Immunology; Mice; Neurotoxins; Prevention; Recombinant Proteins - immunology; Serotypes; Survival; Toxins; vaccine; Vaccines; Vaccines, Subunit - chemistry; Vaccines, Subunit - pharmacology; Vaccines, Synthetic - chemistry; Vaccines, Synthetic - pharmacology; Waterborne diseases
• ISSN: 2072-6651; 2072-6651
• DOI: 10.3390/toxins9090269

There are few available medical countermeasures against botulism and the discontinuation of the pentavalent botulinum toxoid vaccine by the Centers for Disease Control and Prevention in 2011 has resulted in the need for a safe and effective prophylactic alternative. Advances in genetic engineering have resulted in subsequent vaccine efforts being primarily focused on the production of highly purified recombinant protein antigens representing one or more domains of the botulinum neurotoxin. Recombinant subunit vaccines based on the carboxy one-third of the toxin (Hc) developed in our lab against serotypes A-F have been shown to be safe and effective. However, in response to the identification of an ever increasing number of BoNT subtypes with significant amino acid heterogeneity, we have developed catalytically inactive BoNT holoproteins (ciBoNT HPs) in an attempt to elicit greater protective immunity to address these toxin variants. Here we report the production of ciBoNT/B1 HP, ciBoNT/C1 HP, ciBoNT/E1 HP and ciBoNT/F1 HP and compare the immunological and protective abilities of ciBoNT HPs and BoNT/A Hc, BoNT/B Hc, BoNT/C Hc, BoNT/E Hc and BoNT/F Hc vaccines when challenged with homologous and heterologous toxins. Our results suggest the ciBoNT HP vaccines exhibit superior potency after single vaccinations but multiple vaccinations with BoNT/Hc antigens resulted in increased survival rates at the toxin challenge levels used.